Published in December 2018 and last updated in April 2020
The 2018 Farm Bill includes historic provisions that legalize hemp, the low THC cultivars of the Cannabis sativa L. species. When the president signed this landmark legislation into law, it changed how hemp and hemp-derived products like cannabidiol (CBD) are regulated in the U.S.
To help the herbal products industry understand the new regulatory landscape, AHPA produced a free Status Report and webinar to answer industry questions.
April 2020 updates
- Additional information on the USDA Interim Final Rule issued in October 2019
- USDA updates since then, including two portions of the interim final rule for which they will be implementing enforcement discretion
- What growers should be aware of for the 2020 growing season
- FDA developments since the report was last issued – warning letters continue to be issued, the consumer update issued in October 2019, March 2020 FDA report to Congress on CBD regulation, and consideration of legislative options
Free Status Report
AHPA worked with legal and industry experts to develop a new, free resource titled Status Report: Marketing of hemp and cannabidiol (CBD) products in the United States .
This document provides concise and up-to-date information on the status of such operations and products as soon as this legislation is adopted as federal law and taking into account other current and relevant laws and regulations.
This status report was expanded in April 2020 to address the USDA Interim Final Rule in October 2019 and USDA and FDA updates since the last revision of this report.
On Demand Webinar
Recorded on Dec. 19, 2018, this webinar presents more than two hours of expert information on how the Farm Bill could affect companies that want to cultivate hemp crops or sell consumer goods that contain hemp and hemp-derived ingredients, including CBD. It also includes an extended Q&A session that answers to attendees' specific questions.
- Recorded: December 19, 2018
- Duration: 2+ hours
- Cost: $50 for members -- $100 for non members
Veteran herbal industry experts provide insiders' views of the evolving regulatory landscape for companies growing, manufacturing or selling hemp and products with hemp-derived ingredients, including CBD.
- Michael McGuffin, President, AHPA
- Jane Wilson, Director of Program Development, AHPA
- Holly Johnson, Ph.D., Chief Science Officer, AHPA
- Will Woodlee, Esq., Partner, Kleinfeld, Kaplan & Becker
- Pete Evich, Vice President, Van Scoyoc Associates (Q&A)
- Tony Young, Esq., Partner, Kleinfeld, Kaplan & Becker (Q&A)